8 Oversold Biotech Stocks to Invest In Now
On February 5, J.P. Morgan revealed major themes that are expected to affect healthcare in 2026, emphasizing a resurgence of interest in the biopharma sector.
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Marshall Wace LLP Paul Marshall And Ian Wace | 11,655 | $48,485 | 0% |
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $1.30 | 15,335 | $19,992.24 | 52,045 | 2023-08-21 | Filing | |
| $1.25 | 25,000 | $31,245.00 | 57,461 | 2023-08-17 | Filing | |
| $4.58 | 2,000 | $9,150.00 | 3,000 | 2022-05-23 | Filing | |
| $4.52 | 7,500 | $33,900.00 | 32,461 | 2022-05-23 | Filing | |
| $4.53 | 500 | $2,262.50 | 2,500 | 2022-05-18 | Filing |
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $0.26 | 1,800 | $466.38 | 700 | 2022-12-08 | Filing |
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 120 | $253 | 0% |